Raise your Query
Hi! Simply click below and type your query.
Our experts will reply you very soon.
Hi! Simply click below and type your query.
Our experts will reply you very soon.
| Business Type | Supplier, Retailer, Wholesaler |
| Composition of Product | Ceftriaxone 250 mg + Tazobactum 31.25 mg |
| Best Before | 2 Years from manufacturing |
| Pack Type | Vial with SWFI |
| Click to view more | |
Preferred Buyer From
| Location | Worldwide |
Product Details
Ceftriaxone 250mg + Tazobactam 31.25mg Salt Information :
Side Effects of Ceftriaxone 250mg + Tazobactam 31.25mg:
Superinfection; anaphylaxis; diarrhoea; local reactions; blood dyscrasias; rash, fever, pruritus; elevated transaminases and alkaline phosphatase. GI effects; pseudomembranous colitis; hematologic effects; hypersensitivity reactions; CNS disturbances; hypertension; chest pain; edema; moniliasis; rhinitis; dyspnea; hypotension; ileus; syncope; local Inj site reactions; rigors. Potentially Fatal: Pseudomembranous colitis; nephrotoxicity.
Drug Interactions of Ceftriaxone 250mg + Tazobactam 31.25mg:
Probenecid; aminoglycosides; vecuronium, methotrexate; oral anticoagulants; heparin. Potentially Fatal: Disulfiram-like reaction with alcohol. Nephrotoxicity with aminoglycosides and furosemide.
Contraindications of Ceftriaxone 250mg + Tazobactam 31.25mg:
Hypersensitivity to cephalosporins and β-lactamase inhibitors.
Mechanism of Action of Ceftriaxone 250mg + Tazobactam 31.25mg:
Ceftriaxone interferes with the biosynthesis of the peptidoglycan component of the bacterial cell way by binding to and inactivating penicllin-binding proteins (PBPs). Tazobactam is a penicillanic acid sulfone derivative with β-lactamase inhibitory properties. It enhances the activity of β-lactam antibacterials against β-lactamase-producing bacteria. Distribution: Ceftriaxone: 98% bound to plasma proteins; crosses the blood brain barrier. Tazobactam: About 30% bound to plasma proteins; widely distributed to tissues and body fluids. Excretion: Ceftriaxone: Elimination half-life is about 8.7 hr; 33-67% removed as unchanged drug. Tazobactam: Removed mainly via kidneys with 80% of an administered dose as unchanged drug.
Special Precautions for Ceftriaxone 250mg + Tazobactam 31.25mg:
History of penicillin allergy; lactation. Consider possibility of pseudomembranous colitis in patients who present with diarrhoea subsequent to the admin of antibacterial agents. Monitor prothrombin time in patients with impaired vit K synthesis or low vit K stores during treatment. Prolonged treatment may result in overgrowth of nonsusceptible organisms. Caution in patients with a history of GI disease, especially colitis. Discontinue treatment in patients who develop signs/symptoms suggestive of gallbladder disease. Not to be used in hyperbilirubinemic neonates, especially prematures.
